- This is only an interim analysis result of the CUREVAC Covid vaccince!! - Initial analyzes have shown that the effectiveness depends on the age group examined and the virus strains, the company continues. - The vaccine candidate is in the final stage of clinical development. - CEO Franz-Werner Haas announced that one had hoped for stronger results in the interim analysis. - But continue the current study until the final analysis.
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.